Glaxo recalls Augmentin after contamination
Picture : The Hindu
The plasticiser contamination scandal in Taiwan has spread further. Originally detected in food, drinks and health products, the health department detected the presence of di-isodecyl phthalate (DIDP), in amoxicillin clavulanate, under the brand name Augmentin, manufactured by GSK, (Glaxo SmithKline Plc) . The drug is used to treat many antibiotic resistant bacteria, particularly in children.
Taiwan has now followed Hong Kong and banned the drug asking Glaxo to recall the drugs at fault. The contaminated product were manufactured in France, No response has been made in the EU, and it has not featured on the news but India may be close to be asking for a recall too.
Earlier Hong Kong’s Department of Health said in a statement that Diisodecyl phthalate (DIDP) was detected in GSK’s Augmentin powder for syrup 156mg/5ml, a product for children.
A government laboratory test detected the presence of DIDP was two times higher than Europe’s specific migration limit for food contact materials.
DIDP’s safety for human consumption was not well established, but data from animal studies suggested long-term consumption of high levels of DIDP may affect the liver, the government said.
The government said it had stepped up surveillance of pharmaceutical products containing flavouring agents after Chinese media reports that Chinese importers had recalled bottled beverages from Taiwan that were suspected of being contaminated with a cancer-causing plastic additive.
A GlaxoSmithKline spokesman said the company was seeking professional advice on the recall. It said the chemical had not been added intentionally and it belonged to a group of plasticisers that are present in trace compounds in the environment and in many items that are consumed daily.